EMA validates Bristol Myers Squibb's type II variation application for Opdivo plus Yervoy for first─line treatment of ...
Bristol Myers Squibb announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult patients with unresectable or advanced …